Paola A. Rojas

B, Argentina

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Correction: The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer.

Correction: The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer.

Journal: Oncotarget

Published: April 09, 2026

Steroid hormone receptors, exome sequencing and treatment responsiveness of breast cancer patient-derived xenografts originated in a South American country.

Steroid hormone receptors, exome sequencing and treatment responsiveness of breast cancer patient-derived xenografts originated in a South American country.

Journal: Scientific reports

Published: September 10, 2024

Antiprogestins for breast cancer treatment: We are almost ready.

Antiprogestins for breast cancer treatment: We are almost ready.

Journal: The Journal of steroid biochemistry and molecular biology

Published: November 29, 2023

Steroid profile in patients with breast cancer and in mice treated with mifepristone.

Steroid profile in patients with breast cancer and in mice treated with mifepristone.

Journal: Endocrine-related cancer

Published: July 25, 2023

Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial.

Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 30, 2022

Progesterone receptor isoform ratio dictates antiprogestin/progestin effects on breast cancer growth and metastases: A role for NDRG1.

Progesterone receptor isoform ratio dictates antiprogestin/progestin effects on breast cancer growth and metastases: A role for NDRG1.

Journal: International journal of cancer

Published: September 03, 2021

Galectin-1 confers resistance to doxorubicin in hepatocellular carcinoma cells through modulation of P-glycoprotein expression.

Galectin-1 confers resistance to doxorubicin in hepatocellular carcinoma cells through modulation of P-glycoprotein expression.

Journal: Cell death & disease

Published: February 18, 2021

Increased High Molecular Weight FGF2 in Endocrine-Resistant Breast Cancer.

Increased High Molecular Weight FGF2 in Endocrine-Resistant Breast Cancer.

Journal: Hormones & cancer

Published: March 14, 2018

Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor for Antiprogestin Responsiveness.

Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor for Antiprogestin Responsiveness.

Journal: Journal of the National Cancer Institute

Published: July 27, 2016

Nuclear staining of fgfr-2/stat-5 and runx-2 in mucinous breast cancer.

Nuclear staining of fgfr-2/stat-5 and runx-2 in mucinous breast cancer.

Journal: Experimental and molecular pathology

Published: October 21, 2015

The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer.

The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer.

Journal: Oncotarget

Published: June 11, 2014

Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters.

Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters.

Journal: International journal of cancer

Published: February 05, 2014

Showing 1-12 of 14

Last Updated: 09/26/2026